Core Viewpoint - The company, Youzhiyou Biotechnology-B (02496), has announced the publication of clinical trial results for its dual-target bispecific antibody drug M701, which targets Ep CAM and CD3, in the treatment of malignant ascites caused by advanced epithelial tumors. This recognition in an internationally renowned medical journal signifies the clinical value of the innovative therapy [1]. Group I: Clinical Trial Results - The Phase II study aimed to evaluate the efficacy and safety of M701 administered via intraperitoneal infusion in patients with moderate to severe malignant ascites due to advanced epithelial tumors. A total of 84 patients were enrolled, with 43 assigned to the M701 group receiving intraperitoneal infusion after paracentesis [1]. - The median puncture-free survival time for the M701 group was 75 days, compared to 25 days for the control group, showing a significant difference (p=0.0065) [1]. - Subgroup analysis indicated that various cancer types, including gastric, colorectal, and ovarian cancers, benefited from M701 infusion. Patients with a baseline relative lymphocyte count of ≥13% exhibited better efficacy [1]. Group II: Survival Rates - The overall survival time for patients in the M701 group was extended compared to the control group. The six-month survival rates were 33.3% for the M701 group and 12.1% for the control group [1]. - No other serious adverse events were observed in the M701 group, indicating a favorable safety profile for the treatment [1].

Group 1 - Excyte Biopharma Ltd. has officially launched a Phase I clinical trial for its core product YK012, a bispecific antibody targeting CD3/CD19, for primary membranous nephropathy (pMN) in the United States [1] - The trial was registered on ClinicalTrials.gov on November 18, 2025, marking a significant step in Excyte's international research and development in the field of autoimmune diseases [1] - Excyte Biopharma, established in 2016, focuses on the development of bispecific antibody drugs and has a complete development platform with unique technical advantages in drug structure design, affinity optimization, and safety regulation [1] Group 2 - The Changchun New Area Government Investment Fund made a forward-looking investment in Excyte Biopharma in June 2024, providing critical resources for the early-stage development of YK012 and accelerating its clinical progress [2] - This investment reflects the fund's strategic support and precise layout in the field of biopharmaceutical innovation, which will also promote local talent cultivation, technological innovation, and industrial chain aggregation [2] - The ongoing wave of domestic innovative drugs entering international markets will see the Changchun New Area Government Investment Fund continue to support innovative enterprises, effectively promoting regional industrial structure optimization and upgrading [2]

Core Viewpoint - The company has announced mid-term data from a Phase II clinical trial of its dual-targeting bispecific antibody M701 for treating malignant pleural effusion caused by advanced non-small cell lung cancer (NSCLC), showing significant efficacy compared to the control group receiving cisplatin [1][4]. Group 1: Clinical Trial Overview - The Phase II trial (code name: M70103) is a randomized, controlled, multi-center study involving 54 eligible patients with symptomatic malignant pleural effusion after at least one line of systemic therapy [2]. - Patients were randomly assigned in a 1:1 ratio to receive either M701 or cisplatin after thoracentesis [1][2]. - The primary endpoint is puncture-free survival time (Pu FS), while secondary endpoints include objective response rate (ORR), time to next puncture (TTNP), and related symptoms [1]. Group 2: Patient Demographics - The trial included 26 patients in the M701 group and 28 in the cisplatin group, with median ages of 66.5 and 61.5 years, respectively [2]. - Female proportions were 57.7% in the M701 group and 50.0% in the control group, with ECOG performance status scores of 0-1 being 92.3% and 96.4% [2]. - Baseline characteristics were generally balanced between the two groups, with similar proportions of patients having prior thoracentesis and chemotherapy [2]. Group 3: Efficacy Results - M701 demonstrated a longer median puncture-free survival time compared to cisplatin (130 days vs. 85 days, HR=0.80, p=0.542) [3]. - In patients without driver gene mutations, the median survival was not reached for M701 compared to 44.5 days for cisplatin (HR<0.01, p<0.001) [3]. - The objective response rate for malignant pleural effusion was 72.7% for M701 versus 41.7% for cisplatin [3]. Group 4: Safety Results - The incidence of treatment-related adverse events was 3.7% for M701 compared to 10% for cisplatin, with only one serious adverse event related to M701 [3]. - Flow cytometry analysis indicated a significant reduction of Ep CAM+CD45- tumor cells in the pleural effusion after M701 infusion, which was not observed in the cisplatin group [3]. Group 5: Conclusion and Future Plans - M701 shows significant efficacy and good tolerability in treating malignant pleural effusion, particularly in NSCLC patients without driver gene mutations or those with prior chemotherapy [4]. - The ongoing Phase II trial indicates potential for preventing recurrence of pleural effusion, with plans for a pivotal Phase III trial to start in 2026 to validate efficacy and safety in a larger Chinese population [4].

Core Viewpoint - The company Yuzhiyou Biotech (02496) has announced mid-term data from its Phase II clinical trial of the bispecific antibody M701 for treating malignant pleural effusion caused by advanced non-small cell lung cancer (NSCLC), which was presented at the 2025 European Society for Medical Oncology (ESMO) conference [1] Group 1: Clinical Trial Overview - The study is a randomized, controlled, multicenter, open-label Phase II trial (code name: M70103) focusing on malignant pleural effusion in advanced NSCLC [2] - Participants were randomly assigned in a 1:1 ratio to either the treatment group receiving M701 or the control group receiving cisplatin after thoracentesis [2] - The primary endpoint is puncture-free survival (Pu FS), while secondary endpoints include objective response rate (ORR), time to next puncture (TTNP), and related symptoms [2] Group 2: Patient Demographics - As of March 7, 2025, 54 eligible patients with symptomatic malignant pleural effusion were enrolled, with 26 in the treatment group and 28 in the control group [3] - The median age was 66.5 years for the treatment group and 61.5 years for the control group, with a balanced baseline condition between the two groups [3] Group 3: Efficacy Results - The treatment group showed a longer median puncture-free survival of 130 days compared to 85 days in the control group, with a hazard ratio (HR) of 0.80 [4] - Notably, patients without driver gene mutations benefited significantly, with a median survival not reached compared to 44.5 days in the control group [4] - The objective response rate for malignant pleural effusion was 72.7% in the treatment group versus 41.7% in the control group [4] Group 4: Safety Results - The incidence of treatment-related adverse events was 3.7% for M701 compared to 10% for cisplatin, with only one serious adverse event linked to M701 [4] Group 5: Conclusion and Future Plans - M701 demonstrated significant efficacy and good tolerability compared to cisplatin, supporting further clinical development, especially for NSCLC patients without driver gene mutations [5] - A pivotal Phase III trial is planned to start in 2026 to validate the efficacy and safety of M701 in a larger Chinese population [5]

Core Viewpoint - Huahai Pharmaceutical's subsidiary, Shanghai Huatai Biopharmaceutical Co., Ltd., has received FDA approval to conduct Phase I clinical trials for HB0043 in the United States, marking a significant advancement in the treatment of autoimmune diseases [1] Group 1: Product Development - HB0043 is a recombinant humanized IgG1 bispecific antibody targeting both IL-17A and IL-36R, demonstrating high binding and blocking activity [1] - The drug is developed for treating various difficult-to-treat autoimmune diseases, showing stronger efficacy in animal models compared to monoclonal antibodies [1] - HB0043 is the world's first bispecific antibody targeting IL-17A and IL-36R, potentially overcoming the limitations of existing single-target therapies [1] Group 2: Market Potential - Current IL-17A inhibitors and IL-36R monoclonal antibodies have shown positive effects in multiple indications, but there are still limitations in their single-dimensional intervention for some patients [1] - The dual-target approach of HB0043 is expected to provide new treatment strategies for immune-mediated inflammatory skin diseases and fibrotic diseases [1] - The innovative mechanism of HB0043 positions it as a first-in-class (FIC) product with broad potential applications in Th17 and IL-36 related immune-mediated diseases [1]

Core Insights - Huahai Pharmaceutical's subsidiary, Shanghai Huatai Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of HB0043, a bispecific antibody targeting IL-17A and IL-36R, aimed at treating various autoimmune diseases [1][2] Group 1: Product Development - HB0043 is a recombinant humanized IgG1 bispecific antibody that targets both IL-17A and IL-36R, demonstrating high binding and blocking activity [1] - The drug has shown superior efficacy compared to monoclonal antibodies in various animal disease models, including atopic dermatitis, idiopathic pulmonary fibrosis, diabetic nephropathy, and neutrophilic asthma [1] - HB0043 offers a new approach to targeted therapy for immune-mediated inflammatory skin diseases and fibrotic diseases, addressing the limitations of single-factor blocking therapies [1] Group 2: Market Potential - As the first bispecific drug globally targeting both IL-17A and IL-36R, HB0043 is expected to overcome the limitations of existing single-target therapies [2] - Current treatments, such as IL-17A inhibitors and IL-36R monoclonal antibodies, have shown positive effects in multiple indications but may still fall short in addressing inflammation in some patients [2] - The innovative dual-target mechanism of HB0043 positions it as a first-in-class (FIC) therapy with broad potential applications in various Th17/IL-36 related immune-mediated diseases [2]